Prosecution Insights
Last updated: April 19, 2026

Larimar Therapeutics Inc.

3 pending office actions

Portfolio Summary

3
Total Pending OAs
2
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18433336 METHODS FOR TREATING MYELIN ASSOCIATED DISEASES AND MITOCHONDRIA ASSOCIATED DISEASES COFFA, SERGIO 1658 Final Rejection Feb 05, 2024
17627638 USE OF FRATAXIN FOR TREATING LEIGH SYNDROME, FRENCH CANADIAN TYPE REYNOLDS, FRED H 1658 Non-Final OA Jan 14, 2022
16864125 FRATAXIN-SENSITIVE MARKERS FOR DETERMINING EFFECTIVENESS OF FRATAXIN REPLACEMENT THERAPY SITTON, JEHANNE SOUAYA 1682 Final Rejection Apr 30, 2020

Managing Larimar Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month